Functional Restoration of Mouse Nf1 Nonsense Alleles in Differentiated Cultured Neurons

Overview

Journal J Hum Genet

Specialty Genetics

Date 2022 Aug 9

PMID 35945271

Authors

Chan Wu

Sukanya Iyer

Scot A Wolfe

Allan Jacobson

Affiliations

Soon will be listed here.

Abstract

Neurofibromatosis type 1 (NF1), one of the most common autosomal dominant genetic disorders, is caused by mutations in the NF1 gene. NF1 patients have a wide variety of manifestations with a subset at high risk for the development of tumors in the central nervous system (CNS). Nonsense mutations that result in the synthesis of truncated NF1 protein (neurofibromin) are strongly associated with CNS tumors. Therapeutic nonsense suppression with small molecule drugs is a potentially powerful approach to restore the expression of genes harboring nonsense mutations. Ataluren is one such drug that has been shown to restore full-length functional protein in several models of nonsense mutation diseases, as well as in patients with nonsense mutation Duchenne muscular dystrophy. To test ataluren's potential applicability to NF1 nonsense mutations associated with CNS tumors, we generated a homozygous Nf1-3X-FLAG mouse embryonic stem (mES) cell line which recapitulates an NF1 patient nonsense mutation (c.2041 C > T; p.Arg681X). We differentiated Nf1-3X-FLAG mES cells into cortical neurons in vitro, treated the cells with ataluren, and demonstrated that ataluren can promote readthrough of the nonsense mutation at codon 683 of Nf1 mRNA in neural cells. The resulting full-length protein is able to reduce the cellular level of hyperactive phosphorylated ERK (pERK), a RAS effector normally suppressed by the NF1 protein.

Citing Articles

The evolving landscape of NF gene therapy: Hurdles and opportunities.

ODonohue A, Ginn S, Burgio G, Berman Y, Dabscheck G, Schindeler A Mol Ther Nucleic Acids. 2025; 36(1):102475.

PMID: 40034205 PMC: 11872496. DOI: 10.1016/j.omtn.2025.102475.

Emerging Personalized Opportunities for Enhancing Translational Readthrough in Rare Genetic Diseases and Beyond.

Wagner R, Wiessner M, Friedrich A, Zandanell J, Breitenbach-Koller H, Bauer J Int J Mol Sci. 2023; 24(7).

PMID: 37047074 PMC: 10093890. DOI: 10.3390/ijms24076101.

References

Friedman J . Epidemiology of neurofibromatosis type 1. Am J Med Genet. 1999; 89(1):1-6. View

Leier A, Bedwell D, Chen A, Dickson G, Keeling K, Kesterson R . Mutation-Directed Therapeutics for Neurofibromatosis Type I. Mol Ther Nucleic Acids. 2020; 20:739-753. PMC: 7225739. DOI: 10.1016/j.omtn.2020.04.012. View

DeClue J, Cohen B, Lowy D . Identification and characterization of the neurofibromatosis type 1 protein product. Proc Natl Acad Sci U S A. 1991; 88(22):9914-8. PMC: 52837. DOI: 10.1073/pnas.88.22.9914. View

Gutmann D, Wood D, Collins F . Identification of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci U S A. 1991; 88(21):9658-62. PMC: 52777. DOI: 10.1073/pnas.88.21.9658. View

Bernards A, Snijders A, Hannigan G, Murthy A, Gusella J . Mouse neurofibromatosis type 1 cDNA sequence reveals high degree of conservation of both coding and non-coding mRNA segments. Hum Mol Genet. 1993; 2(6):645-50. DOI: 10.1093/hmg/2.6.645. View

Gutmann D, Collins F . The neurofibromatosis type 1 gene and its protein product, neurofibromin. Neuron. 1993; 10(3):335-43. DOI: 10.1016/0896-6273(93)90324-k. View

Xu G, OConnell P, Viskochil D, Cawthon R, Robertson M, Culver M . The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell. 1990; 62(3):599-608. DOI: 10.1016/0092-8674(90)90024-9. View

Martin G, Viskochil D, Bollag G, McCabe P, Crosier W, Haubruck H . The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell. 1990; 63(4):843-9. DOI: 10.1016/0092-8674(90)90150-d. View

Ballester R, Marchuk D, Boguski M, Saulino A, Letcher R, Wigler M . The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell. 1990; 63(4):851-9. DOI: 10.1016/0092-8674(90)90151-4. View

10.

Kim H, Ratner N, Roberts T, Stiles C . Schwann cell proliferative responses to cAMP and Nf1 are mediated by cyclin D1. J Neurosci. 2001; 21(4):1110-6. PMC: 6762237. View

11.

Dasgupta B, Dugan L, Gutmann D . The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J Neurosci. 2003; 23(26):8949-54. PMC: 6740397. View

12.

Hegedus B, Dasgupta B, Shin J, Emnett R, Hart-Mahon E, Elghazi L . Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms. Cell Stem Cell. 2008; 1(4):443-57. DOI: 10.1016/j.stem.2007.07.008. View

13.

Brown J, Diggs-Andrews K, Gianino S, Gutmann D . Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP/PKA/ROCK-dependent manner. Mol Cell Neurosci. 2011; 49(1):13-22. PMC: 3237958. DOI: 10.1016/j.mcn.2011.08.008. View

14.

Philpott C, Tovell H, Frayling I, Cooper D, Upadhyaya M . The NF1 somatic mutational landscape in sporadic human cancers. Hum Genomics. 2017; 11(1):13. PMC: 5480124. DOI: 10.1186/s40246-017-0109-3. View

15.

Gutmann D, Ferner R, Listernick R, Korf B, Wolters P, Johnson K . Neurofibromatosis type 1. Nat Rev Dis Primers. 2017; 3:17004. DOI: 10.1038/nrdp.2017.4. View

16.

Stenson P, Mort M, Ball E, Chapman M, Evans K, Azevedo L . The Human Gene Mutation Database (HGMD): optimizing its use in a clinical diagnostic or research setting. Hum Genet. 2020; 139(10):1197-1207. PMC: 7497289. DOI: 10.1007/s00439-020-02199-3. View

17.

He F, Jacobson A . Nonsense-Mediated mRNA Decay: Degradation of Defective Transcripts Is Only Part of the Story. Annu Rev Genet. 2015; 49:339-66. PMC: 4837945. DOI: 10.1146/annurev-genet-112414-054639. View

18.

Osborn M, Upadhyaya M . Evaluation of the protein truncation test and mutation detection in the NF1 gene: mutational analysis of 15 known and 40 unknown mutations. Hum Genet. 1999; 105(4):327-32. DOI: 10.1007/s004399900135. View

19.

Bashyam M . Nonsense-mediated decay: linking a basic cellular process to human disease. Expert Rev Mol Diagn. 2009; 9(4):299-303. DOI: 10.1586/erm.09.18. View

20.

Anastasaki C, Morris S, Gao F, Gutmann D . Children with 5'-end gene mutations are more likely to have glioma. Neurol Genet. 2017; 3(5):e192. PMC: 5610042. DOI: 10.1212/NXG.0000000000000192. View